Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RNXT
stocks logo

RNXT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
335.50K
+680.23%
-0.083
-31.25%
516.67K
+162.27%
-0.100
+25%
--
--
-0.100
+25%
Estimates Revision
The market is revising No Change the revenue expectations for RenovoRx, Inc. (RNXT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.39%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-23.39%
In Past 3 Month
Wall Street analysts forecast RNXT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNXT is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast RNXT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNXT is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.950
sliders
Low
3.00
Averages
5.50
High
12.00
Current: 0.950
sliders
Low
3.00
Averages
5.50
High
12.00
Alliance Global
Buy
maintain
$3
2025-11-14
Reason
Alliance Global
Price Target
$3
2025-11-14
maintain
Buy
Reason
Alliance Global lowered the firm's price target on RenovoRx to $3 from $3.50 and keeps a Buy rating on the shares after the company reported Q3 earnings that were within expectations. The firm cites lower forecasts and modestly higher expected dilution for its reduced target.
Ascendiant
Edward Woo
Buy
maintain
$11
2025-06-05
Reason
Ascendiant
Edward Woo
Price Target
$11
2025-06-05
maintain
Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$3
2025-04-04
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$3
2025-04-04
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Initiates
$3
2025-03-27
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$3
2025-03-27
Initiates
Strong Buy
Reason
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$8.25 → $9
2024-12-10
Reason
Ascendiant Capital
Edward Woo
Price Target
$8.25 → $9
2024-12-10
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for RenovoRx Inc (RNXT.O) is -2.48, compared to its 5-year average forward P/E of -3.01. For a more detailed relative valuation and DCF analysis to assess RenovoRx Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.01
Current PE
-2.48
Overvalued PE
-1.36
Undervalued PE
-4.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.94
Current PS
0.00
Overvalued PS
13.40
Undervalued PS
-5.53
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

RNXT News & Events

Events Timeline

(ET)
2025-11-13
16:42:39
RenovoRx announces Q3 earnings per share of 8 cents, matching two forecasts of 8 cents.
select
2025-11-06 (ET)
2025-11-06
08:46:20
RenovoRx Names Timothy Donahue to Strategic Advisory Board
select
2025-10-09 (ET)
2025-10-09
08:44:23
RenovoRx Enhances Scientific Advisory Board by Adding Baere
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-17NASDAQ.COM
Repare Surges 30%, Nuvalent Rises 9% in After-Hours Biotech Gains

  • Repare Therapeutics Acquisition: Repare Therapeutics Inc. surged 30.32% after announcing a definitive agreement for XenoTherapeutics to acquire all outstanding shares, with a transaction expected to close in Q1 2026.

  • Senti Biosciences Financial Results: Senti Biosciences, Inc. reported a net loss of $18.1 million for Q3 2025, with cash reserves decreasing significantly from the previous year.

  • Applied Therapeutics Performance: Applied Therapeutics, Inc. saw an 8.15% increase in after-hours trading, reporting a reduced net loss of $19.0 million for Q3 2025 compared to the same period in 2024.

  • Nuvalent's Upcoming Data Release: Nuvalent, Inc. gained 9.33% after announcing plans for a webcast to discuss pivotal data for its investigational drug neladalkib in patients with advanced ALK-positive non-small cell lung cancer.

[object Object]
Preview
1.0
11-04Newsfilter
RenovoRx CEO Shaun Bagai to Speak at Canaccord Genuity MedTech, Diagnostics, Digital Health & Services Forum on November 20th

  • Company Overview: RenovoRx, Inc. is a life sciences company focused on developing targeted oncology therapies, particularly through its FDA-cleared drug-delivery device, RenovoCath, which aims to address high unmet medical needs in cancer treatment.

  • Upcoming Event: CEO Shaun Bagai will present at the Canaccord Genuity MedTech Forum on November 20, 2025, discussing the commercialization progress of RenovoCath and updates on the Phase III TIGeR-PaC clinical trial for intra-arterial gemcitabine in pancreatic cancer.

  • Clinical Trials and Studies: The company is conducting a Phase III trial for its drug-device combination product candidate, IAG, and has launched a post-marketing observational registry study to assess long-term safety and survival outcomes for patients treated with RenovoCath.

  • Commercialization Efforts: RenovoRx is actively commercializing its TAMP technology and has received initial purchase orders for RenovoCath, with several customers placing repeat orders, indicating strong market demand and interest from high-volume cancer treatment centers.

[object Object]
Preview
9.0
10-17Newsfilter
Natural Killer Cell Treatments Drive $254B Shift in Immunotherapy Market

  • Advancements in Cancer Immunotherapy: MIT and Harvard scientists have engineered CAR-NK cells that evade the immune system, enhancing cancer destruction and enabling immediate off-the-shelf treatments. The global cancer immunotherapy market is projected to grow significantly, driven by innovations in cellular therapies and biomarker-driven drug development.

  • GT Biopharma's Clinical Progress: GT Biopharma is advancing its Phase 1 trial of GTB-3650 for treating relapsed or refractory blood cancers, showing promising early results in immune activation without significant side effects. The company plans to file for human trials of its solid tumor-targeting therapy, GTB-5550, by late 2025.

  • Evaxion's Personalized Cancer Vaccine: Evaxion A/S is set to present two-year data from its Phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine, demonstrating a 69% overall response rate in advanced melanoma patients. The company emphasizes the importance of personalized therapies in oncology.

  • RenovoRx and EDAP TMS Innovations: RenovoRx has initiated a registry study to evaluate its drug-delivery device, RenovoCath, for solid tumors, while EDAP TMS gained national attention for its non-invasive Focal One Robotic HIFU treatment for prostate cancer, highlighting advancements in minimally invasive cancer therapies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is RenovoRx Inc (RNXT) stock price today?

The current price of RNXT is 0.95 USD — it has increased 5.09 % in the last trading day.

arrow icon

What is RenovoRx Inc (RNXT)'s business?

RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

arrow icon

What is the price predicton of RNXT Stock?

Wall Street analysts forecast RNXT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNXT is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is RenovoRx Inc (RNXT)'s revenue for the last quarter?

RenovoRx Inc revenue for the last quarter amounts to 266.00K USD, decreased % YoY.

arrow icon

What is RenovoRx Inc (RNXT)'s earnings per share (EPS) for the last quarter?

RenovoRx Inc. EPS for the last quarter amounts to -0.08 USD, decreased -20.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for RenovoRx Inc (RNXT)'s fundamentals?

The market is revising No Change the revenue expectations for RenovoRx, Inc. (RNXT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.39%.
arrow icon

How many employees does RenovoRx Inc (RNXT). have?

RenovoRx Inc (RNXT) has 10 emplpoyees as of December 05 2025.

arrow icon

What is RenovoRx Inc (RNXT) market cap?

Today RNXT has the market capitalization of 34.82M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free